Dr. Goy on Lenalidomide as Management for Patients With MCL

Andre Goy, MD, MS
Published: Monday, Apr 17, 2017



Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL).

Lenalidomide is approved by the FDA for the treatment of patients with MCL, Goy explains. Moreover, its clinical activity in heavily pretreated patients, as reported from pivotal data, demonstrated a 33% response rate, an 8% complete response (CR) rate, and a median duration of response between 16 and 17 months. Several of these patients, he adds, were refractory to chemotherapy. Therefore, the R-squared data—known as rituximab (Rituxan) plus lenalidomide—in the relapsed/refractory setting is also impressive but is associated with more myeloid toxicity.

However, in the frontline setting of R-squared as treatment for MCL, it also took up to 1 year for patients to achieve a CR in the clinical trial; however, he says, it was impressive even in the high-risk population. This could potentially lead to a new frontline standard of care in MCL, though more follow-up is needed.
SELECTED
LANGUAGE


Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy of lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL).

Lenalidomide is approved by the FDA for the treatment of patients with MCL, Goy explains. Moreover, its clinical activity in heavily pretreated patients, as reported from pivotal data, demonstrated a 33% response rate, an 8% complete response (CR) rate, and a median duration of response between 16 and 17 months. Several of these patients, he adds, were refractory to chemotherapy. Therefore, the R-squared data—known as rituximab (Rituxan) plus lenalidomide—in the relapsed/refractory setting is also impressive but is associated with more myeloid toxicity.

However, in the frontline setting of R-squared as treatment for MCL, it also took up to 1 year for patients to achieve a CR in the clinical trial; however, he says, it was impressive even in the high-risk population. This could potentially lead to a new frontline standard of care in MCL, though more follow-up is needed.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x